Menu

World’s First Commercial iPSC Cell Plant Opens in Japan

The $340 million, 30,000-square-foot center will produce cells for therapeutic applications.

Mar 23, 2018
Jim Daley

Human induced pluripotent stem cellsCHRISTINE HALE, WIKIMEDIAA pharmaceutical company based in Osaka, Japan, opened a regenerative medicine center yesterday (March 22) that will produce cells derived from induced pluripotent stem (iPS) cells for commercial applications. The center is the first plant of its kind globally. It will initially produce cells for use in clinical trials.

The Sumitomo Dainippon Manufacturing Plant for Regenerative Medicine & Cell Therapy will allow the company to “gain an overwhelming advantage in the market of medical and pharmaceutical products,” Masayo Tada, president of Sumitomo Dainippon Pharma, tells The Asahi Shimbun. “We will occupy a definite position in the field of regenerative medicine.” On April 1, Hiroshi Nomura, currently the company’s executive vice president, will replace Tada as president, according to The Pharma Letter. Tada will transition to the position of chairman.

Existing iPSC production facilities, including the National Institutes of Health’s Center for Regenerative Medicine and WiCell’s Stem Cell Bank, have made cells available to researchers. The Sumitomo Dainippon plant will be the first to offer cells for commercial purposes.

Construction of the center cost approximately 3.6 billion yen ($342.7 million USD), according to a statement. The facility has more than 30,000 square feet of floor space divided among three autonomous zones that will produce different types of cells. Company officials say that each zone will be able to produce enough cells to treat hundreds of patients per year, according to The Asahi Shimbun

The company will use iPS cells produced at Kyoto University’s Center for iPS Cell Research and Application (CiRA) for cell production. Sumitomo Dainippon and CiRA have previously collaborated to develop iPS cell-based regenerative medicine technology for patients with Parkinson's disease.

See “Banking on iPSCs

Sumitomo Dainippon plans to make regenerative medicine one of its core businesses and endeavors to increase sales to 200 billion yen ($1.8 billion USD) by 2030, according to The Asahi Shimbun.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.